

2019年 英文誌掲載論文

Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease.	Tsukiyama T, Kobayashi K, Nakaya M, Iwatani C, Seita Y, Tsuchiya H, Matsushita J, Kitajima K, Kawamoto I, Nakagawa T, Fukuda K, Iwakiri T, Izumi H, Itagaki I, Kume S, Maegawa H, Nishinakamura R, Nishio S, Nakamura S, Kawauchi A, Ema M.	Nat Commun.
Safety and effectiveness of ipragliflozin in elderly versus non-elderly Japanese type 2 diabetes mellitus patients: 12 month interim results of the STELLA-LONG TERM study.	Maegawa H, Tobe K, Nakamura I, Uno S.	Curr Med Res Opin.
Preserving β -cell function is the major determinant of diabetes remission following laparoscopic sleeve gastrectomy in Japanese obese diabetic patients.	Ugi S, Morino K, Yamaguchi T, Yamamoto H, Kaida S, Miyazawa I, Sato D, Sekine O, Fujita Y, Kashiwagi A, Tani M, Maegawa H.	Endocr J.
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long-term Use study.	Tobe K, Maegawa H, Tabuchi H, Nakamura I, Uno S.	J Diabetes Investig.
Efficacy of metformin on postprandial plasma triglyceride concentration by administration timing in patients with type 2 diabetes mellitus: A randomized cross-over pilot study.	Sato D, Morino K, Ogaku S, Tsuji A, Nishimura K, Sekine O, Ugi S, Maegawa H.	J Diabetes Investig.
Carotid Intima-Media Thickness and Plaque in Apparently Healthy Japanese Individuals with an Estimated 10-Year Absolute Risk of CAD Death According to the Japan Atherosclerosis Society (JAS) Guidelines 2012: The Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA).	Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T, Kadowaki T, Takashima N, Hisamatsu T, Nakamura Y, Kasagi F, Maegawa H, Kashiwagi A, Ueshima H; SESSA Research Group and for the NIPPON DATA80/90 Research Group.	J Atheroscler Thromb.
Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.	Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.	Diabetes Obes Metab.
Diabetes management and treatment approaches outside of North America and West Europe in 2006 and 2015.	Tabesh M, Magliano DJ, Tanamas SK, Surmont F, Bahendeka S, Chiang CE, Elgart JF, Gagliardino JJ, Kalra S, Krishnamoorthy S, Luk A, Maegawa H, Motala AA, Pirie F, Ramachandran A, Tayeb K, Vikulova O, Wong J, Shaw JE.	Acta Diabetol.
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.	Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.	Diabetes Obes Metab.
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.	Inoue H, Morino K, Ugi S, Tanaka-Mizuno S, Fuse K, Miyazawa I, Kondo K, Sato D, Ohashi N, Ida S, Sekine O, Yoshimura M, Murata K, Miura K, Arima H, Maegawa H; SUMS-ADDIT-1 Research group.	J Diabetes Investig.
Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014.	Kume S, Araki SI, Ugi S, Morino K, Koya D, Nishio Y, Haneda M, Kashiwagi A, Maegawa H.	J Diabetes Investig.
Protein O-GlcNAcylation Is Essential for the Maintenance of Renal Energy Homeostasis and Function via Lipolysis during Fasting and Diabetes.	Sugahara S, Kume S, Chin-Kanasaki M, Tomita I, Yasuda-Yamahara M, Yamahara K, Takeda N, Osawa N, Yanagita M, Araki SI, Maegawa H.	J Am Soc Nephrol.
Combined Effects of Energy Intake and Physical Activity on Obesity in Japanese Patients with Type 2 Diabetes (JDDM 50): A Cross-Sectional Study.	Hatta M, Fujihara K, Morikawa SY, Takeda Y, Ishii D, Horikawa C, Kato M, Yokoyama H, Kurihara Y, Iwasaki K, Miyazawa K, Yamazaki K, Tanaka S, Maegawa H, Sone H.	Diabetes Ther.
Advanced Technology for Gene Delivery with Homing Peptides to Spinal Cord through Systemic Circulation in Mice.	Terashima T, Ogawa N, Sato T, Katagi M, Nakae Y, Okano J, Maegawa H, Kojima H.	Mol Ther Methods Clin Dev.
Microbiome potentiates endurance exercise through intestinal acetate production.	Okamoto T, Morino K, Ugi S, Nakagawa F, Lemecha M, Ida S, Ohashi N, Sato D, Fujita Y, Maegawa H.	Am J Physiol Endocrinol Metab.
Association of blood levels of marine omega-3 fatty acids with coronary calcification and calcium density in Japanese men.	Sekikawa A, Mahajan H, Kadowaki S, Hisamatsu T, Miyagawa N, Fujiyoshi A, Kadota A, Maegawa H, Murata K, Miura K, Edmundowicz D, Ueshima H; SESSA Research Group.	Eur J Clin Nutr.
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.	Nakamura I, Maegawa H, Tobe K, Uno S.	Adv Ther.
Total energy expenditure is comparable between patients with and without diabetes mellitus: Clinical Evaluation of Energy Requirements in Patients with Diabetes Mellitus (CLEVER-DM) Study.	Morino K, Kondo K, Tanaka S, Nishida Y, Nakae S, Yamada Y, Ugi S, Fuse K, Miyazawa I, Ohi A, Nishida K, Kurihara M, Sasaki M, Ebine N, Sasaki S, Katsukawa F, Maegawa H.	BMJ Open Diabetes Res Care
A role for bone marrow-derived cells in diabetic nephropathy.	Nobuta H, Katagi M, Kume S, Terashima T, Araki SI, Maegawa H, Kojima H, Nakagawa T.	FASEB J.
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).	Tabuchi H, Maegawa H, Tobe K, Nakamura I, Uno S.	Endocr J